Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 1034834, 7 pages
http://dx.doi.org/10.1155/2016/1034834
Research Article

Thiopurines in the Management of Crohn’s Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study

1Division of Gastroenterology, McGill University Health Center, 1650 Cedar Avenue, C7-200, Montreal, QC, Canada H3G 1A4
2Technology Assessment Unit, McGill University Health Center, 687 Pine Avenue West, Room R4.09, Montreal, QC, Canada H3A 1A1
3Unite de Pharmacologie Clinique, Centre Hospitalier Universitaire de Sainte-Justine, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada H3T 1C4

Received 22 July 2015; Accepted 24 September 2015

Copyright © 2016 Amine Benmassaoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. N. Brooke, D. C. Hoffmann, and E. T. Swarbrick, “Azathioprine for Crohn's disease,” The Lancet, vol. 2, no. 7621, pp. 612–614, 1969. View at Google Scholar · View at Scopus
  2. “Approved names,” The British Medical Journal, vol. 2, no. 5526, article 1378, 1966.
  3. L. Chouchana, C. Narjoz, P. Beaune, M.-A. Loriot, and X. Roblin, “Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 1, pp. 15–36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. H. Present, S. J. Meltzer, M. P. Krumholz, A. Wolke, and B. I. Korelitz, “6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity,” Annals of Internal Medicine, vol. 111, no. 8, pp. 641–649, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Bastida, P. Nos, M. Aguas et al., “Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 9, pp. 775–782, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Cuffari, Y. Théorêt, S. Latour, and G. Seidman, “6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity,” Gut, vol. 39, no. 3, pp. 401–406, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Chaparro, I. Ordás, E. Cabré et al., “Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients,” Inflammatory Bowel Diseases, vol. 19, no. 7, pp. 1404–1410, 2013. View at Publisher · View at Google Scholar
  8. L. T. Ford, S. C. Cooper, M. J. Lewis, and J. D. Berg, “Reference intervals for thiopurine S-methyltransferase activity in red blood cells using 6-thioguanine as substrate and rapid non-extraction liquid chromatography,” Annals of Clinical Biochemistry, vol. 41, part 4, pp. 303–308, 2004. View at Google Scholar
  9. R. M. Weinshilboum and S. L. Sladek, “Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity,” The American Journal of Human Genetics, vol. 32, no. 5, pp. 651–662, 1980. View at Google Scholar · View at Scopus
  10. X.-W. Dong, Q. Zheng, M.-M. Zhu, J.-L. Tong, and Z.-H. Ran, “Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 16, no. 25, pp. 3187–3195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. Gisbert, P. Niño, L. Rodrigo, C. Cara, and L. G. Guijarro, “Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients,” The American Journal of Gastroenterology, vol. 101, no. 12, pp. 2769–2776, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Zhu and Q. Cao, “Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine,” Chinese Medical Journal, vol. 125, no. 20, pp. 3665–3670, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Hindorf, M. Lindqvist, C. Peterson et al., “Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease,” Gut, vol. 55, no. 10, pp. 1423–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. G. R. Lichtenstein, S. B. Hanauer, and W. J. Sandborn, “Management of Crohn's disease in adults,” The American Journal of Gastroenterology, vol. 104, no. 2, pp. 465–483, 2009. View at Publisher · View at Google Scholar
  15. M. V. Relling, E. E. Gardner, W. J. Sandborn et al., “Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing,” Clinical Pharmacology and Therapeutics, vol. 89, no. 3, pp. 387–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Yip, M. Woodward, M. T. Abreu, and M. P. Sparrow, “How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice,” Inflammatory Bowel Diseases, vol. 14, no. 4, pp. 514–518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Chisick, C. Oleschuk, and C. N. Bernstein, “The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease,” Canadian Journal of Gastroenterology, vol. 27, no. 1, pp. 39–43, 2013. View at Google Scholar · View at Scopus
  18. A. Ansari, M. Arenas, S. M. Greenfield et al., “Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 8, pp. 973–983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” Canadian Journal of Gastroenterology, vol. 19, pp. 5–36, 2005. View at Google Scholar
  20. L. T. Ford and J. D. Berg, “Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technique,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 798, no. 1, pp. 111–115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Chande, D. J. Tsoulis, and J. K. MacDonald, “Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease,” The Cochrane Database of Systematic Reviews, vol. 4, Article ID CD000545, 2013. View at Google Scholar · View at Scopus
  22. E. Prefontaine, L. R. Sutherland, J. K. Macdonald, and M. Cepoiu, “Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease,” Cochrane Database of Systematic Reviews, vol. 21, no. 1, Article ID CD000067, 2009. View at Publisher · View at Google Scholar
  23. J. P. Gisbert and F. Gomollón, “Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review,” American Journal of Gastroenterology, vol. 103, no. 7, pp. 1783–1800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. W. R. Connell, M. A. Kamm, J. K. Ritchie, and J. E. Lennard-Jones, “Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience,” Gut, vol. 34, no. 8, pp. 1081–1085, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. J. W. Winter, D. Gaffney, D. Shapiro et al., “Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 9, pp. 1069–1077, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Sahasranaman, D. Howard, and S. Roy, “Clinical pharmacology and pharmacogenetics of thiopurines,” European Journal of Clinical Pharmacology, vol. 64, no. 8, pp. 753–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Mazor, E. Koifman, H. Elkin et al., “Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease,” Current Drug Safety, vol. 8, no. 3, pp. 181–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. P. Gisbert and M. Chaparro, “Systematic review with meta-analysis: inflammatory bowel disease in the elderly,” Alimentary Pharmacology and Therapeutics, vol. 39, no. 5, pp. 459–477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Beaugerie, N. Brousse, A. M. Bouvier et al., “Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study,” The Lancet, vol. 374, no. 9701, pp. 1617–1625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Shung, B. Abraham, J. Sellin, and J. K. Hou, “Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review,” Digestive Diseases and Sciences, vol. 60, no. 5, pp. 1132–1140, 2015. View at Publisher · View at Google Scholar · View at Scopus